Amyloid-Journal of Protein Folding Disorders

Papers
(The TQCC of Amyloid-Journal of Protein Folding Disorders is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee266
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee105
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial104
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis58
ATTRv amyloidosis Italian Registry: clinical and epidemiological data52
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis50
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines45
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation40
Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis32
Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding30
Association between spinal stenosis and wild-type ATTR amyloidosis25
Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen25
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group24
Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma23
Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies23
Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11C-Pittsburgh compound B PET imaging23
Next generation flow cytometry for MRD detection in patients with AL amyloidosis22
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres22
TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients19
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients19
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis18
New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden17
The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease16
DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis16
Amyloidosis from the patient perspective: the French daily impact of amyloidosis study16
Dialysis-related amyloidosis associated with a novel β2-microglobulin variant14
Quantification of cardiac amyloid with [18F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis14
Cerebral amyloid angiopathy in a 51-year-old patient with embolization by dura mater extract and surgery for nasopharyngeal angiofibroma at age 1714
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure13
Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience13
A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis12
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis11
Cardiac sympathetic denervation in wild-type transthyretin amyloidosis10
Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type10
A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)10
Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial10
Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience10
Proteomic analysis shows that the main constituent of subepidermal localised cutaneous amyloidosis is not galectin-79
Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)9
Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study9
Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy8
The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients8
Metabolomics analysis for diagnosis and biomarker discovery of transthyretin amyloidosis8
The role of serial 99mTc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis8
Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays8
CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis7
Clinicopathological features of clinically undiagnosed sporadic transthyretin cardiac amyloidosis: a forensic autopsy-based series7
Subclinical retinal angiopathy associated with hereditary transthyretin amyloidosis – assessed with optical coherence tomography angiography7
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis7
Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease7
0.043696880340576